VERV vs. ATXS, KALV, APLT, YMAB, TVTX, AVTE, ABUS, IGMS, LRMR, and OCS
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Astria Therapeutics (ATXS), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Y-mAbs Therapeutics (YMAB), Travere Therapeutics (TVTX), Aerovate Therapeutics (AVTE), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), Larimar Therapeutics (LRMR), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Verve Therapeutics (NASDAQ:VERV) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
Verve Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Astria Therapeutics has lower revenue, but higher earnings than Verve Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Astria Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -1,226.51%. Verve Therapeutics' return on equity of -37.35% beat Astria Therapeutics' return on equity.
97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by insiders. Comparatively, 2.9% of Astria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Astria Therapeutics received 537 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 72.55% of users gave Astria Therapeutics an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Verve Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 450.92%. Astria Therapeutics has a consensus target price of $22.50, indicating a potential upside of 141.16%. Given Verve Therapeutics' higher possible upside, analysts clearly believe Verve Therapeutics is more favorable than Astria Therapeutics.
In the previous week, Verve Therapeutics had 11 more articles in the media than Astria Therapeutics. MarketBeat recorded 13 mentions for Verve Therapeutics and 2 mentions for Astria Therapeutics. Astria Therapeutics' average media sentiment score of 0.99 beat Verve Therapeutics' score of 0.60 indicating that Astria Therapeutics is being referred to more favorably in the news media.
Summary
Verve Therapeutics beats Astria Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
